Two populations of ovine bone marrow-derived dendritic cells can be generated with recombinant GM-CSF and separated on CD11b expression.
Whereas studies on dendritic cells in rodents rely largely on bone marrow-derived dendritic cells (BM-DCs), no data are available about BM-DCs in sheep, a species that is largely used for immunology and transplantation studies. We have developed a culture protocol to produce ovine BM-DCs, using 6x(His)-tagged recombinant GM-CSF which was purified from baculovirus-infected insect cells. When ovine bone marrow progenitors were cultured in the presence of recombinant GM-CSF, large numbers of CD11c-positive cells were generated after 6-7 days. The phenotypic appearance of BM-DCs was assessed by flow cytometry and electron microscopy. Two DC subsets were identified that expressed different levels of MHC class II molecules, differed in receptor-mediated endocytosis, and could be separated on CD11b expression. When separated cells were incubated with microbial products, they react differently to those that are considered the TLR2 and TLR4 agonists in other species. Indeed, although CD11b(int/hi) cells were partially resistant to maturation induced by lipoteichoic acid or lipopolysaccharide, MHC class II upregulation was observed on CD11b(dull) cells. Moreover, these cells had strong stimulatory capacity for CD4 T cells when assayed in allogeneic reactions. This protocol will help analyzing ovine DC interactions with pathogens, and enables future studies on the development of vaccines.
Foulon
Eliane
E
INRA, Toulouse, France.
Foucras
Gilles
G
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology* / Q000276:immunology / Q000378:metabolism; D039481:CD11b Antigen / Q000096:biosynthesis* / Q000276:immunology; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology / Q000378:metabolism; D004705:Endocytosis / Q000187:drug effects / Q000276:immunology; D005434:Flow Cytometry / Q000379:methods; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis / Q000276:immunology; D008070:Lipopolysaccharides / Q000494:pharmacology; D011994:Recombinant Proteins; D012377:Rodentia; D012756:Sheep; D013234:Stem Cells / Q000166:cytology* / Q000276:immunology / Q000378:metabolism; D013682:Teichoic Acids / Q000494:pharmacology; D013997:Time Factors; D051195:Toll-Like Receptor 2 / Q000819:agonists / Q000096:biosynthesis / Q000276:immunology; D051197:Toll-Like Receptor 4 / Q000819:agonists / Q000096:biosynthesis / Q000276:immunology; D014181:Transplantation Immunology / Q000187:drug effects; D014612:Vaccines / Q000276:immunology
D039481:CD11b Antigen; D000949:Histocompatibility Antigens Class II; D008070:Lipopolysaccharides; D011994:Recombinant Proteins; D013682:Teichoic Acids; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D014612:Vaccines; C009900:lipoteichoic acid; D016178:Granulocyte-Macrophage Colony-Stimulating Factor